Zacks: Analysts Anticipate Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Post Quarterly Sales of $71.31 Million

Analysts expect Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to post sales of $71.31 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Alnylam Pharmaceuticals’ earnings. The lowest sales estimate is $61.50 million and the highest is $79.29 million. Alnylam Pharmaceuticals reported sales of $21.03 million during the same quarter last year, which would suggest a positive year over year growth rate of 239.1%. The business is scheduled to issue its next earnings report on Thursday, February 6th.

According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full year sales of $220.35 million for the current year, with estimates ranging from $209.57 million to $227.35 million. For the next year, analysts anticipate that the business will report sales of $427.53 million, with estimates ranging from $385.45 million to $470.70 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.17) by $0.25. The business had revenue of $70.06 million during the quarter, compared to analysts’ expectations of $57.14 million. Alnylam Pharmaceuticals had a negative net margin of 485.73% and a negative return on equity of 52.88%. The business’s revenue for the quarter was up 3284.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.56) earnings per share.

Several brokerages have issued reports on ALNY. Stifel Nicolaus set a $116.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Zacks Investment Research cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $93.00 target price for the company. in a report on Wednesday, September 18th. Bank of America began coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday. They issued a “buy” rating and a $110.00 target price for the company. Piper Jaffray Companies set a $145.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 10th. Finally, Cowen decreased their target price on shares of Alnylam Pharmaceuticals from $147.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $111.50.

Shares of Alnylam Pharmaceuticals stock opened at $90.58 on Thursday. The company has a quick ratio of 5.22, a current ratio of 5.38 and a debt-to-equity ratio of 0.17. Alnylam Pharmaceuticals has a 52-week low of $60.27 and a 52-week high of $96.08. The company has a 50-day simple moving average of $84.57 and a two-hundred day simple moving average of $78.09.

In related news, CEO John Maraganore sold 49,456 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $79.45, for a total transaction of $3,929,279.20. Following the completion of the sale, the chief executive officer now directly owns 239,449 shares in the company, valued at $19,024,223.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Barry E. Greene sold 58,913 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $89.99, for a total transaction of $5,301,580.87. Following the sale, the president now owns 111,851 shares of the company’s stock, valued at $10,065,471.49. The disclosure for this sale can be found here. 3.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ALNY. Maverick Capital Ltd. grew its position in Alnylam Pharmaceuticals by 31.9% during the second quarter. Maverick Capital Ltd. now owns 4,236,016 shares of the biopharmaceutical company’s stock valued at $307,365,000 after buying an additional 1,025,629 shares during the period. Vanguard Group Inc. grew its position in Alnylam Pharmaceuticals by 7.6% during the second quarter. Vanguard Group Inc. now owns 9,316,686 shares of the biopharmaceutical company’s stock valued at $676,018,000 after buying an additional 657,595 shares during the period. Farallon Capital Management LLC grew its position in Alnylam Pharmaceuticals by 120.0% during the second quarter. Farallon Capital Management LLC now owns 1,100,000 shares of the biopharmaceutical company’s stock valued at $79,816,000 after buying an additional 600,000 shares during the period. Baillie Gifford & Co. grew its position in Alnylam Pharmaceuticals by 9.3% during the second quarter. Baillie Gifford & Co. now owns 6,213,470 shares of the biopharmaceutical company’s stock valued at $450,850,000 after buying an additional 528,966 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth approximately $28,946,000. Institutional investors own 93.51% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Story: Risk Tolerance

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply